Peptide Vaccines for Liver Cancer Show Promise in Early Clinical Trials | Research

The takeaway

Phase I/II clinical trials of peptide vaccines targeting GPC3 and other cancer antigens in hepatocellular carcinoma demonstrate safety and immunogenicity, with neoantigen vaccines representing the next frontier.

Up to 70% post-surgical recurrence
Highlighting the urgent need for adjuvant therapies like peptide vaccines in HCC

What the researchers found

Peptide vaccines targeting GPC3 have shown safety and immune activation in HCC clinical trials, and neoantigen vaccines represent a promising next step with preclinical data supporting clinical trial initiation.

Why it matters

Liver cancer has high recurrence rates (up to 70% after surgery) and limited treatment options. Peptide vaccines could help prevent recurrence and treat advanced disease by training the immune system to attack cancer cells.

The numbers in context

HCC 6th most common cancer; 70% relapse after surgery; GPC3, WT-1, AFP, ROBO1, FOXM1 targets; Phase I/II trials

How the study worked

Review of Phase I/II clinical trials of peptide vaccines in HCC, discussion of candidate tumor antigens, and presentation of preclinical neoantigen vaccine data.

Who was studied

Review of hepatocellular carcinoma patients in peptide vaccine trials

What this study cannot tell us

Review of early-phase trials with small patient numbers. Neoantigen data is preclinical only. Peptide vaccines alone have historically shown modest clinical responses in solid tumors.

How to read the evidence

Review of Phase I/II clinical trials with preclinical neoantigen data. Early-stage clinical evidence demonstrating safety and immunogenicity.

When this study was published

Published in 2021, during rapid advances in cancer immunotherapy including the approval of atezolizumab/bevacizumab for HCC.

The bigger picture

Cancer immunotherapy has transformed oncology, but liver cancer has been slower to benefit. Peptide vaccines, combined with the recent success of immune checkpoint inhibitors (atezolizumab/bevacizumab) in HCC, could create powerful combination strategies for this difficult-to-treat cancer.

Questions still open

Could peptide vaccines combined with checkpoint inhibitors improve HCC outcomes?
Will personalized neoantigen vaccines be practical and affordable for HCC patients?
Which HCC patients are most likely to benefit from peptide vaccination?

Common questions

What are peptide cancer vaccines and how do they work?

Peptide cancer vaccines are small protein fragments designed to train the immune system to recognize and attack cancer cells. In liver cancer, they target proteins like GPC3 that are overexpressed on tumor cells, stimulating T cells to seek out and destroy cancer.

Are peptide vaccines available for liver cancer patients now?

They are still in clinical trials (Phase I/II). While early results show safety and immune activation, larger trials are needed to prove they extend survival. The most promising future direction is personalized neoantigen vaccines targeting each patient's unique tumor mutations.

Read the original research

Peptide-Based Vaccines for Hepatocellular Carcinoma: A Review of Recent Advances.

Journal of hepatocellular carcinoma, 8, 1035-1054

View on PubMed ↗Publisher’s paper ↗

Citation

Charneau, Jimmy; Suzuki, Toshihiro; Shimomura, Manami; Fujinami, Norihiro; Nakatsura, Tetsuya. (2021). Peptide-Based Vaccines for Hepatocellular Carcinoma: A Review of Recent Advances.. Journal of hepatocellular carcinoma, 8, 1035-1054. https://doi.org/10.2147/JHC.S291558